Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.1K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.1K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.1K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.1K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

1.4K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical utility of an evolving cholestasis gene panel in 10,000 children and adults.

Frontiers in pediatrics·2026
Same author

Optimizing approach to liver biochemistry abnormalities in cystic fibrosis pediatrics: Balancing efficiency and risk-benefit.

Clinics and research in hepatology and gastroenterology·2026
Same author

Elevated serum aminotransferases in an infant with failure to thrive: A clinicopathological case report.

JPGN reports·2026
Same author

Maralixibat Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome: A Post Hoc Integrated Analysis From Two Clinical Trials.

The Journal of pediatrics·2026
Same author

Epidemiologic Incentive to Eliminate Hepatitis C Virus in More Children.

JAMA network open·2026
Same author

Phenotypic personalized tacrolimus dosing: a step toward precision immunosuppression in liver transplantation.

Hepatobiliary surgery and nutrition·2026

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K

Hepatitis B and C.

Wikrom Karnsakul1, Kathleen B Schwarz2

  • 1Pediatric Liver Center, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, CMSC 2-117, Baltimore, MD 21287, USA.

Pediatric Clinics of North America
|May 16, 2017
PubMed
Summary
This summary is machine-generated.

Chronic viral hepatitis, caused by Hepatitis B (HBV) and C (HCV) viruses, poses a global health challenge. While effective treatments exist for HCV, new therapies are needed for HBV to achieve a functional cure.

Keywords:
Direct-acting antiviral agentsHepatitis BHepatitis CPegylated interferonSpontaneous viral clearanceSustained virologic response

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Chronic viral hepatitis represents a significant global health concern and economic burden.
  • Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the primary etiologies of chronic viral hepatitis in the United States.
  • Many infections remain asymptomatic until adulthood, complicating early detection and intervention.

Purpose of the Study:

  • To review the current therapeutic landscape for chronic viral hepatitis caused by HBV and HCV.
  • To highlight the advancements in HCV treatment and the ongoing development of novel therapies for HBV.
  • To underscore the unmet need for more effective treatments, particularly for achieving a functional cure in HBV infection.

Main Methods:

  • Review of existing literature on antiviral therapies for HBV and HCV.
  • Analysis of current treatment guidelines and clinical trial outcomes.
  • Synthesis of data on approved medications and emerging direct-acting antiviral agents.

Main Results:

  • Effective therapies, including pegylated interferon and ribavirin, are available for HCV, with direct-acting antivirals in pediatric trials.
  • Approved treatments for HBV include alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir.
  • Current HBV therapies rarely achieve a functional cure, indicating a need for improved treatment strategies.

Conclusions:

  • Significant progress has been made in managing HCV, but HBV treatment remains suboptimal.
  • The development of novel therapeutic agents is crucial for achieving a functional cure for HBV.
  • Continued research is essential to address the global health threat posed by chronic viral hepatitis.